Connection

ELENI EFSTATHIOU to Survival Rate

This is a "connection" page, showing publications ELENI EFSTATHIOU has written about Survival Rate.
Connection Strength

0.258
  1. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021 11; 22(11):1541-1559.
    View in: PubMed
    Score: 0.076
  2. Re-admissions for delayed complications after cytoreductive surgery and HIPEC. Acta Chir Belg. 2016 Apr; 116(2):96-100.
    View in: PubMed
    Score: 0.052
  3. Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience. Urol Oncol. 2024 Sep; 42(9):291.e13-291.e25.
    View in: PubMed
    Score: 0.023
  4. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res. 2021 06 01; 27(11):3253-3264.
    View in: PubMed
    Score: 0.018
  5. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999.
    View in: PubMed
    Score: 0.017
  6. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015 May; 22(5):1570-5.
    View in: PubMed
    Score: 0.012
  7. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol. 2010 Nov; 85(11):863-7.
    View in: PubMed
    Score: 0.009
  8. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010 Oct; 24(10):1769-78.
    View in: PubMed
    Score: 0.009
  9. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC Cancer. 2006 Sep 25; 6:228.
    View in: PubMed
    Score: 0.007
  10. Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology. 2006; 70(4):265-72.
    View in: PubMed
    Score: 0.007
  11. Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data. Anticancer Res. 2006 Jul-Aug; 26(4B):3175-81.
    View in: PubMed
    Score: 0.007
  12. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res. 2005 Dec 01; 11(23):8384-90.
    View in: PubMed
    Score: 0.006
  13. Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res. 2005 Sep-Oct; 25(5):3553-8.
    View in: PubMed
    Score: 0.006
  14. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005 May; 97(2):436-41.
    View in: PubMed
    Score: 0.006
  15. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group. Gynecol Oncol. 2002 Jun; 85(3):476-82.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.